# FORM 4

# UNITED

STATES SECURITIES AND EXCHANGE COMMISSION	OMB APPROVAL				
Washington, D.C. 20549	OMB Number:	3235-02			
	Estimated average burden hours per				
OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	response	1			

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)																		
1. Name and Address of Reporting Person *Flynn James E					Issuer Name and Ticker or Trading Symbol     Cabaletta Bio, Inc. [CABA]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director Officer (give title below)  X. Other (specify below)					
(Last) (First) (Middle) 780 THIRD AVENUE, 37TH FLOOR,					3. Date of Earliest Transaction (Month/Day/Year) 10/24/2019								Officer (give title below) X Other (specify below)  Possible Member of 10% Group					
(Street) NEW YORK, NY 10017				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group FilingCheck Applicable Line)  Form filed by One Reporting Person  X_ Form filed by More than One Reporting Person						
(City) (State) (Zip)					Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned													
1.Title of Security (Instr. 3)			2. Transactic (Month/Day	/Year) l	any	med on Date, i Day/Yea	if (Ir	Transaction Constr. 8)	ode	4. Securities A Disposed of (I (Instr. 3, 4 and		or .	5. Amount of Securities Beneficially Owned Following Rep Transaction(s) (Instr. 3 and 4)		ving Reported	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	V	Amount	(A) or (D)	Price					(I) (Instr. 4)	
Common Stock			10/29/201	9				C		464,253	A	<u>(1)</u>	464,253	1			I	Through Deerfield Special Situations Fund, L.P. (2) (3)
Common Stock			10/29/201	9				С		464,253	A	<u>(1)</u>	464,253				I	Through Deerfield Private Design Fund IV, L.P. (2) (3)
Common Stock			10/29/201	9				P		700,000	A	\$ 11	700,000	)			I	Through Deerfield Partners, L.P. (2) (3)
D : 1 D :	I. 6 1 1	e	111 4 1	r a														
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.  Persons who respond to the collection of information contained in this form are not required to  SEC 14										C 1474 (9-02)								
				Tabl	e II - De	erivative	Securi	ities Acquired,	Dispose	d of, or Benef	icially Owned		ently valid	d OMB control number.				
(e.g., puts, calls, warrants, options, convertible securities)							7 Title	tle and Amount of Underlying Securities 8. Price of 9. Numb			9. Number of	10.	11. Nature					
(Instr. 3)	Exercise Price of Derivative Security	(Month/Day/Year)	Execution Date, if any (Month/Day/Year)	(Instr. 8)							and 4)	. Or Chachying Securities	Derivative Security (Instr. 5)	Derivative Securities	Ownership Form of Derivative Security:	of Indirect Beneficial Ownership		
				Code	e	v	(A)	(D)		Date Exercisable	Expiration Date	Title		Amount or Number of Shares		Following Reported Transaction(s) (Instr. 4)	Direct (D) or Indirect (I) (Instr. 4)	(Instr. 4)
Series B Preferred Stock	<u>(1)</u>	10/29/2019		С				696,37	79	(1)	Ш		mmon tock	464,253	<u>(1)</u>	0	I	Through Deerfield Private Design Fund IV, L.P. (2) (3)
Series B Preferred Stock	(1)	10/29/2019		С				696,37	79	(1)	(1)		nmon tock	464,253	<u>(1)</u>	0	I	Through Deerfield Special Situations Fund,

### **Reporting Owners**

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Flynn James E 780 THIRD AVENUE, 37TH FLOOR NEW YORK, NY 10017		X		Possible Member of 10% Group				
Deerfield Mgmt IV, L.P. 780 THIRD AVENUE, 37TH FLOOR NEW YORK, NY 10017		X		Possible Member of 10% Group				
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 780 THIRD AVENUE, 37TH FLOOR NEW YORK, NY 10017		X		Possible Member of 10% Group				
Deerfield Private Design Fund IV, L.P. 780 THIRD AVENUE 37TH FLOOR NEW YORK, NY 10017		X		Possible Member of 10% Group				
Deerfield Mgmt L.P. 780 THIRD AVENUE 37TH FLOOR NEW YORK, NY 10017		X		Possible Member of 10% Group				
Deerfield Special Situations Fund, L.P. 780 THIRD AVENUE 37TH FLOOR NEW YORK, NY 10017		X		Possible Member of 10% Group				
DEERFIELD PARTNERS, L.P. 780 THIRD AVENUE 37TH FLOOR NEW YORK, NY 10017		Х		Possible Member of 10% Group				

#### **Signatures**

/s/ Jonathan Isler, Attorney-in-Fact	10/30/2019
**Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each share of Series B Preferred Stock automatically converted into 0.6666667 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering (on an adjusted basis, after giving effect to the 1-for-1.5 reverse stock split of the Issuer's common stock effected by

  (2) This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. ("Fund IV"). Deerfield Mg

  Company, L.P.
- (3) In accordance with Instruction 4(b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities

#### Remarks:

Jonathan Isler, Attorney-in-

Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to Proteon Therapeutics, Inc. filed with the Securities and Exchange Commission on August 4, 2017 by Deerfield Special Situation

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

#### Joint Filer Information

Names: Deerfield Mgmt IV, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P.,

Deerfield Private Design Fund IV, L.P., Deerfield Partners, L.P. and Deerfield Special Situations Fund, L.P.

Address: 780 Third Avenue, 37<sup>th</sup> Floor

New York, NY 10017

Designated Filer: James E. Flynn

Issuer and Ticker Symbol: Cabaletta Bio, Inc. [CABA]

Date of Event Requiring Statement: October 29, 2019

The undersigned, Deerfield Mgmt IV, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Partners, L.P. and Deerfield Special Situations Fund, L.P. are jointly filing the attached Statement of Changes in Beneficial Ownership on Form 4 with James E. Flynn with respect to the beneficial ownership of securities of Cabaletta Bio, Inc.

Signatures:

DEERFIELD MGMT, L.P.

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD MANAGEMENT COMPANY, L.P. By: Flynn Management LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD SPECIAL SITUATIONS FUND, L.P.

By: Deerfield Mgmt, L.P., General Partner By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD MGMT IV, L.P.

By: J.E. Flynn Capital IV, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD PRIVATE DESIGN FUND IV, L.P. By: Deerfield Mgmt IV, L.P., General Partner By: J.E. Flynn Capital IV, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD PARTNERS, L.P.

By: Deerfield Mgmt, L.P., General Partner By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact